FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma
FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Low-Calorie Diet Linked to Improved Chemo Response in Leukemia Low-Calorie Diet Linked to Improved Chemo Response in Leukemia
A low-sugar/low-carb diet and exercise regimen was associated with an improved response to chemotherapy in a pilot study in children and adolescents with leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 7, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Tislelizumab Plus Chemo Slows Advanced Squamous NSCLC
Progression - free survival significantly longer with tislelizumab plus chemotherapy versus chemotherapy alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 5, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Tislelizumab Plus Chemo Slows Advanced Squamous NSCLC
MONDAY, April 5, 2021 -- For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 5, 2021 Category: Pharmaceuticals Source Type: news

'A life-changer': NHS England rolls out five-minute breast cancer treatment
New ‘quicker and kinder’ treatment combining drugs cuts length of time some patients have to spend in hospitalA new breast cancer treatment will cut the amount of time some patients have to spend in hospital from two and a half hours to five minutes.The treatment, called Phesgo, is being rolled out across England by the NHS and will be offered to breast cancer patients undergoing chemotherapy. It will be available to people with HER2-positive breast cancer, which accounts for 15% of all such cancers.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 5, 2021 Category: Science Authors: PA Media Tags: Breast cancer NHS Health Society Source Type: news

NHS patients to be offered cancer treatment at home
Specialist nurses from top cancer centre The Christie NHS Foundation Trust in Manchester are already offering at-home chemotherapy and immunotherapy to 250 patients a day. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2021 Category: Consumer Health News Source Type: news

Low-calorie diet and mild exercise improve survival for young people with leukemia
In some cancers, including leukemia in children and adolescents, obesity can negatively affect survival outcomes. Obese young people with leukemia are 50% more likely to relapse after treatment than their lean counterparts.Now,a study led by researchers at UCLA and Children’s Hospital Los Angeles has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program imm...
Source: UCLA Newsroom: Health Sciences - April 1, 2021 Category: Universities & Medical Training Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Diet + exercise + chemo = increased survival in youth with leukemia
(Children's Hospital Los Angeles) Study conducted at Children's Hospital Los Angeles shows that diet and exercise led to reduced risk of remaining cancer cells after one month of chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2021 Category: Cancer & Oncology Source Type: news

Diet and exercise may increase efficacy of chemotherapy for children with cancer
(American Society of Hematology) New research published today in the journal Blood Advances is the first to show that restricting calories, reducing fat and sugar intake, and increasing physical activity may boost the effectiveness of chemotherapy for older children and adolescents with leukemia. This intervention, which improved chemotherapy outcomes for children being treated at two institutions, will be further studied through a national trial later this year. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2021 Category: Cancer & Oncology Source Type: news

Discontinuing chemotherapy for oesophageal cancer cost effective?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

A ‘Game Changer’ for Patients With Esophageal Cancer
A drug that unleashes the immune system offers a rare glimmer of hope for those with a cancer that resists most treatments. (Source: NYT Health)
Source: NYT Health - March 31, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Clinical Trials Esophageal Cancer Drugs (Pharmaceuticals) Chemotherapy Radiation Alcoholic Beverages Bristol Myers Squibb Company New England Journal of Medicine East Asia United States Source Type: news

Surgery Can Boost Outcomes After Chemo for People With Pancreatic Cancer
WEDNESDAY, March 31, 2021 -- Even in patients with stage 2 pancreatic cancer, surgery is typically worthwhile after chemotherapy, because it appears to extend patients'lives, a new study concludes. In stage 2 cancer, the tumor has already grown... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 31, 2021 Category: General Medicine Source Type: news

Chemo for glioblastoma may work better in morning than evening
(Washington University School of Medicine) An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. While researchers are investigating potential new therapies via ongoing clinical trials, a new study from Washington University in St. Louis suggests that a minor adjustment to the current standard treatment -- giving chemotherapy in the morning rather than the evening -- could add a few months to patients' survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Cytoreduction in Advanced Ovarian Cancer:'Keep the Status Quo'Cytoreduction in Advanced Ovarian Cancer:'Keep the Status Quo '
A retrospective case-control study showed that optimal cytoreductive surgery is an independent predictor of overall survival, even when controlling for response to chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 30, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

COVID Vaccine Gives Less Protection for Some Cancer Patients
Millions of people across the United States have begun receiving their COVID-19 vaccines, and restrictions are lifting in many public spaces such as restaurants and bars. Mesothelioma patients may be looking forward to returning to life as it was before the pandemic. However, a new study reports that the COVID-19 vaccine may not sufficiently protect patients with compromised or weakened immune systems. The study results suggest that people with cancer or who are undergoing cancer treatment may still be highly vulnerable to COVID-19 even after their vaccination. Researchers published their findings earlier this m...
Source: Asbestos and Mesothelioma News - March 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

With Drug Shortages and Errors on the Rise, Oncology Pharmacists are...
A report from the Institute of Medicine titled “Frequency of chemotherapy medication errors: A systematic review” estimates that medication errors with chemotherapeutic drugs are the second most...(PRWeb March 30, 2021)Read the full story at https://www.prweb.com/releases/with_drug_shortages_and_errors_on_the_rise_oncology_pharmacists_are_vital_members_of_patient_care_teams_in_era_of_a_pandemic_according_to_hopa/prweb17814869.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 30, 2021 Category: Pharmaceuticals Source Type: news

Vaccine advice for adults living with adults who are immunosuppressed
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the government to prioritise people for the coronavirus (COVID-19) vaccine who are over 16 and living with adults who have weakened immune systems, such as those with blood cancer, HIV or those on immunosuppressive treatment including chemotherapy. (Source: NHS Networks)
Source: NHS Networks - March 30, 2021 Category: UK Health Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
(American College of Surgeons) Patients with stage II pancreatic cancer who are treated with chemotherapy followed by resection (an operation that removes the cancerous part of the organ, structure or tissue) live nearly twice as long as patients who receive only chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 26, 2021 Category: Cancer & Oncology Source Type: news

Potential COVID-19 treatment identified in UCLA-led lab study
This study identified a new potential therapy that could help the global fight against COVID-19 and support populations that have been disproportionately affected by this deadly disease.”Drugs are categorized as small molecules when their individual molecules are tiny enough that they can penetrate to where they are needed. The researchers screened 430 drugs from among the approximately 200,000 compounds in CNSI ’sMolecular Screening Shared Resource libraries. They identified 34  that demonstrated at least some ability to halt the coronavirus, and eight that did so at relatively lower doses, before zeroing...
Source: UCLA Newsroom: Health Sciences - March 24, 2021 Category: Universities & Medical Training Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) March 23, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 23, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves pembrolizumab for esophageal or GEJ carcinoma
FDA approved pembrolizumab (Keytruda, Merck Sharp& Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma who are not candidates for surgical resection or definitive chemoradiation. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

New breed of drug that reduces deaths from bladder cancer
The medicines, which are known as antibody-drug conjugates (ADCs), carry out chemotherapy-like attacks on cancer cells but don't cause side effects such as hair loss, fatigue and nausea. (Source: the Mail online | Health)
Source: the Mail online | Health - March 20, 2021 Category: Consumer Health News Source Type: news

Ablative Radiation Extends Life in Unresectable Pancreatic Cancer Ablative Radiation Extends Life in Unresectable Pancreatic Cancer
Increasing the radiation dose by making adjustments for respiratory and gastrointestinal functions improves the outcome, when given with induction chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Drug Trial Snapshot: DAURISMO
DAURISMO is used to treat adults with newly-diagnosed acute myeloid leukemia (AML). It is to be used in patients who•are 75 years of age or older, or•have other medical conditions that prevent the use of standard chemotherapy. AML is a rapidly progressing cancer that forms in the bone marrow and (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 18, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Some Mesothelioma Patients May Benefit from Second Radical Surgery
This study should elicit a call of hands for centers to share their experiences, to say either do it, or not do it,” Elsayed said. “Right now, you just don’t find a good number of centers doing that second operation.” Earlier Mesothelioma Surgery Studies  This most recent report focused on three smaller studies totaling 40 patients involved in a second major surgery with a curative intent for mesothelioma. In the first group of 16 patients, there was a median survival of 20.4 months after the second surgery for those with epithelial cell type, but only 7.4 months survival for those wit...
Source: Asbestos and Mesothelioma News - March 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma
(ECOG-ACRIN Cancer Research Group) The DREAM3R phase 3 clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. DREAM3R aims to enroll 480 patients with non-epithelioid or epithelioid subtype. Patients will be randomized 2:1 to receive durvalumab immunotherapy plus 4-6 cycles of chemotherapy or chemotherapy alone. Patients in the experimental group will continue to receive durvalumab after chemotherapy until disease progression, unacceptable toxicity, or patient withdrawal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

Double trouble for drug-resistant cancers
(Duke-NUS Medical School) New research from Duke-NUS Medical School, and the Agency for Science, Technology and Research identifies chemotherapy-resistant cancers' escape mechanism, which offers new anti-cancer treatment options. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 15, 2021 Category: Cancer & Oncology Source Type: news

Chemotherapy with fewer side effects may be on the way
(University of Queensland) University of Queensland pain researchers used the anti-inflammatory drug anakinra to significantly reduce the nerve pain which is a debilitating side effect of the chemotherapy drug vincristine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 14, 2021 Category: Cancer & Oncology Source Type: news

Study finds cancer cells may evade chemotherapy by going dormant
(Weill Cornell Medicine) Cancer cells can dodge chemotherapy by entering a state that bears similarity to certain kinds of senescence, a type of " active hibernation " that enables them to weather the stress induced by aggressive treatments aimed at destroying them, according to a new study by scientists at Weill Cornell Medicine. These findings have implications for developing new drug combinations that could block senescence and make chemotherapy more effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2021 Category: Cancer & Oncology Source Type: news

ASCO, CSCO Outline'Best Practices' for Nasopharyngeal Carcinoma ASCO, CSCO Outline'Best Practices' for Nasopharyngeal Carcinoma
New evidence-based recommendations provide guidance on when to give radiotherapy and chemotherapy to patients with nasopharyngeal carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Link Between Women with Mesothelioma and Survival Genes
Men with mesothelioma outnumber women four to one. However, numerous studies have shown that women with mesothelioma often have a survival advantage over men. Now, scientists might have a better understanding of why. Researchers have identified a gene that predicts the prognosis and treatment outcome for women with malignant pleural mesothelioma. The research took place as part of the International Mesothelioma Program at Brigham and Women’s Hospital in Boston. Dr. Assunta De Rienzo led the new study after years of research highlighting the sex-based disparity among mesothelioma patients. “The goal is ...
Source: Asbestos and Mesothelioma News - March 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Novel Radiopharmaceutical Beats Cabazitaxel in mCRPC Novel Radiopharmaceutical Beats Cabazitaxel in mCRPC
The first comparator study shows that the novel radiopharmaceutical Lu-PSMA-6170 bettered chemotherapy for metastatic castration-resistant prostate cancer (mCRPC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Therapy sneaks into hard layer of pancreatic cancer tumor and destroys it from within
(University of California - San Diego) Researchers at University of California San Diego School of Medicine and Moores Cancer Center demonstrated that a new tumor-penetrating therapy could enhance the effects of chemotherapy, reduce the spread of pancreatic cancer and increase survival in animal models. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 9, 2021 Category: Biology Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Investor Update - March 8, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Media News - March 8, 2021 Category: Pharmaceuticals Source Type: news

New inhibitor found to combat drug-resistant cancer cells
(Martin-Luther-Universit ä t Halle-Wittenberg) A new substance could improve the treatment of persistent cancers. Researchers at Martin Luther University Halle-Wittenberg (MLU) and the University of Greifswald have developed a new inhibitor that makes drug-resistant tumour cells respond again to chemotherapy. The new substance blocks a protein in the cancer cells that normally transports the cancer drugs back out of the cells. The results were published in the scientific journal " Molecules " . (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2021 Category: International Medicine & Public Health Source Type: news

Oncotarget: Sensitivity testing on ovarian cancer cells isolated from malignant ascites
(Impact Journals LLC) The aim of this @Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 8, 2021 Category: Cancer & Oncology Source Type: news

How bone marrow regenerates after chemotherapy
This study could help develop a novel therapeutic approach for chemotherapy-induced myelosuppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 5, 2021 Category: Cancer & Oncology Source Type: news

Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 4, 2021 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

New ASH Guidelines: VTE Prevention, Treatment in Cancer Patients New ASH Guidelines: VTE Prevention, Treatment in Cancer Patients
The American Society of Hematology has issued new guidelines on the use of thromboprophylaxis for ambulatory patients receiving cancer chemotherapy who are at low venous thromboembolism (VTE) risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASH Issues Guidance for Preventing, Treating VTE in Cancer
Use of thromboprophylaxis not recommended for ambulatory patients at low risk for VTE who are receiving chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 1, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Surgery, Journal, Source Type: news

Enfortumab Vedotin Shows Promise for Urothelial Carcinoma Enfortumab Vedotin Shows Promise for Urothelial Carcinoma
The antibody-drug conjugate enfortumab vedotin is superior to chemotherapy in patients with previously treated advanced urothelial carcinoma, primary results of the EV-301 trial show.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Single cell sequencing opens new avenues for eradicating leukemia at its source
(Center for Genomic Regulation) Cancer stem cells that elude conventional treatments like chemotherapy drive long-term cancer growth and relapse. These cells are difficult to isolate and study because of their low abundance and similarity to other stem cells. Researchers have created a new method that can distinguish cancer stem cells, mature cancer cells and otherwise healthy stem cells based on their genetics and gene expression. The findings open new avenues for cancer research personalised medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2021 Category: International Medicine & Public Health Source Type: news

Natural product isolated from sea sponge tested against cancer cells
(Far Eastern Federal University) Scientists from Far Eastern Federal University (FEFU) together with Russian and German colleagues, continue studying antitumor compounds synthesized based on bioactive molecules isolated from a sea sponge. One of them fights cancer cells resistant to standard chemotherapy, and at the same time has an interesting dual mechanism of action. A related article appears inMarine Drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news

No Survival Benefit to Primary Resection Before Chemo in CRC No Survival Benefit to Primary Resection Before Chemo in CRC
Contrary to previous reports, primary tumor resection prior to chemotherapy did not confer a survival benefit in colorectal cancer patients in a randomized phase 3 study in Japan.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news